-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Methylprednisolone-d3
Category | SARS-CoV |
Description | Methylprednisolone-d3 is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. |
Product Information
Synonyms | U 7532-d3 |
Molecular Weight | 377.49 |
Molecular Formula | C22H27D3O5 |
Canonical SMILES | C[C@@]12[C@](CC[C@]2(O)C(CO)=O)([H])[C@@]3([2H])[C@@]([C@H](C1([2H])[2H])O)([H])[C@@]4(C([C@H](C3)C)=CC(C=C4)=O)C |
Purity | ≥98% (HPLC) |
Solubility | In vitro: 10 mM in DMSO |
Appearance | Solid powder |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Complexity | 754 |
Exact Mass | 377.22815429 |
In Vitro | Methylprednisolone is typically used for its anti-inflammatory effects. Common uses include arthritis therapy and short-term treatment of bronchial inflammation or acute bronchitis due to various respiratory diseases. Methylprednisolone is used both in the treatment of acute periods and long-term management of autoimmune diseases, most notably systemic lupus erythematosus. It is also used for vestibular neuritis. After six months the patients who were treated with methylprednisolone within eight hours of their injury had significant improvement as compared with those given placebo in motor function (neurologic change scores of 16.0 and 11.2, respectively; P = 0.03) and sensation to pinprick (change scores of 11.4 and 6.6; P = 0.02) and touch (change scores, 8.9 and 4.3; P = 0.03). Benefit from methylprednisolone was seen in patients whose injuries were initially evaluated as neurologically complete, as well as in those believed to have incomplete lesions. |
Target | Glucocorticoid Receptor; Autophagy; SARS-CoV |
XLogP3-AA | 1.9 |